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Abstract
Erythema nodosum leprosum (ENL) is a severe multisystem immune mediated complica-
tion of borderline lepromatous leprosy and lepromatous leprosy. ENL is associated with
skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis
and nephritis. The treatment of ENL requires immunosuppression, which is often required
for prolonged periods of time and may lead to serious adverse effects. ENL and its treat-
ment is associated with increased mortality and economic hardship. Improved, evidence-
based treatments for ENL are needed; however, defining the severity of ENL and outcome
measures for treatment studies is difficult because of the multiple organ systems involved.
A cross-sectional study was performed, by the members of the Erythema Nodosum Lepro-
sum International STudy (ENLIST) Group, of patients with ENL attending seven leprosy
referral centres in Brazil, Ethiopia, India, Nepal, the Philippines and the United Kingdom.
We systematically documented the clinical features and type of ENL, its severity and the
drugs used to treat it. Patients with chronic ENL were more likely to be assessed as having
severe ENL. Pain, the most frequent symptom, assessed using a semi-quantitative scale
was significantly worse in individuals with “severe” ENL. Our findings will determine the
items to be included in a severity scale of ENL which we are developing and validating. The
study also provides data on the clinical features of ENL, which can be incorporated into a
definition of ENL and used for outcome measures in treatment studies.
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Author Summary
Leprosy is caused by a bacterium and is curable with a combination of antibiotics known
as multi-drug therapy, which patients take for six or 12 months. However, a significant
proportion of leprosy patients experience severe inflammation in their skin, nerves and
other organs known as erythema nodosum leprosum (ENL). ENL is a severe complication
of leprosy which can occur before, during, or after completion of antibacterial treatment.
ENL causes severe morbidity affecting not only the skin, but also bones, joints, eyes,
nerves, testes and kidneys. ENL may be fatal and it has been shown that the adverse effects
of corticosteroid treatment also contribute to mortality. An effective treatment for ENL is
thalidomide but this is not available in many leprosy endemic countries or is severely con-
strained by availability, cost and justified concerns about teratogenicity. Thalidomide,
despite its effectiveness, is rarely used as a first line agent. Other effective drugs need to be
identified to reduce the burden of this condition. In order to establish which treatments
will be effective in ENL it is necessary to have a clear picture of the clinical features of the
disease and how these influence severity. This is the first systematic study of ENL to define
these and will help in developing tools to facilitate treatment studies of this severe, debili-
tating complication of leprosy.
Introduction
Leprosy reactions are a significant cause of morbidity. Erythema nodosum leprosum (ENL) is
an immunological complication affecting individuals with lepromatous leprosy (LL)[1]. ENL
affects approximately 50% of individuals with LL and 5–10% of borderline lepromatous (BL)
leprosy patients [1, 2].
ENL is a multisystem disorder characterised by the occurrence of crops of tender skin
lesions. The histology of ENL lesions classically shows an intense perivascular infiltrate of neu-
trophils throughout the dermis and subcutis [3]. Tissue oedema and vessels exhibiting fibrinoid
necrosis may also be present. The pathophysiology of ENL has not been fully elucidated though
immune complexes and cellular immunity mechanisms have been reported be involved. ENL
has some features of an immune complex mediated disease. Direct immunofluorescence stud-
ies have demonstrated granular deposits of immunoglobulin and complement in the dermis in
ENL lesions but not in those of uncomplicated LL disease [4]. There is evidence of T lympho-
cyte and macrophage activation and expression of mRNA for TNFα and IL12 in the skin [5].
ENL may occur before, during or after successful completion of multi-drug therapy (MDT).
An individual may have a single acute episode of ENL while others develop chronic forms last-
ing many years [1, 6]. It is not clear why some individuals develop ENL and others do not
although polymorphisms in NOD2 [7], IL6 [8] and NRAMP1 [9] genes have been associated
with increased susceptibility for developing ENL.
The inflammatory state of ENL causes significant morbidity and mortality if untreated.
Patients are treated with corticosteroids and thalidomide which are used for prolonged periods
of many months or years. Many patients require high doses of corticosteroids to control their
disease which leads to complications and a significant number of deaths associated with long-
term use of these drugs [6, 10]. Thalidomide is not available in many countries or is severely
restricted because of the risk of teratogenicity and cost. Thalidomide is also associated with
adverse effects such as somnolence, nausea, neurotoxicity, dizziness and thromboembolism
which may limit its use. ENL is also associated with severe economic hardship[11].
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The identification of other agents for controlling ENL and the development of a quantitative
measure to assess the severity of ENL have been highlighted as priority research areas [12, 13].
Since the introduction of multi-drug therapy (MDT) there have been only four randomised
controlled trials involving just 136 individuals and only three of these involved some form of
allocation concealment[14–17].
An understanding of the clinical features of ENL is important in the accurate diagnosis and
successful management of the condition. The clinical features are also important as meaningful
items for a severity scale and to determine appropriate outcome measures for intervention
studies. Descriptions of leprosy reactions appear in many early monographs but the term ENL
was first coined by Murata in 1912[18]. However there are no prospective studies detailing the
clinical features and relative frequencies of organ involvement in ENL since the introduction of
MDT. A retrospective study of the clinical features of ENL in 94 patients who had attended a
“neuritis clinic” at a leprosy referral centre in Nepal were reported by Feuth et al[19]. This
study reported that the most frequent non-cutaneous clinical signs in this cohort were:
enlarged or tender nerves (99%), new and/or old nerve function impairment (NFI) (88%) and
fever (78%).
A cross-sectional study was performed to gather data on the prevalence of the various clini-
cal features of ENL including: the morphology of skin lesions, the presence of NFI and other
extra-cutaneous manifestations. An assessment of the severity of pain associated with ENL was
made. The severity and type of ENL (acute, recurrent or chronic) was recorded.
Methods
The study was conducted in seven leprosy referral centres in Brazil, Ethiopia, India (two cen-
tres), Nepal, the Philippines and the United Kingdom by the ENLIST Group.
Leprosy was or had been diagnosed in individuals who had hypopigmented, anaesthetic
skin patches and/or thickened nerves and/or acid-fast bacilli on slit skin smears. Leprosy was
classified according to the classification of Ridley and Jopling[20] using clinical, histological
and bacteriological indices.
The case definition of ENL was: “a patient diagnosed with leprosy has ENL if s/he has crops
of tender cutaneous or subcutaneous lesions”. In the absence of cutaneous signs ENL could
also be diagnosed if a patient with leprosy had fever or malaise and histological features consis-
tent with ENL in a tissue biopsy.
The nature of ENL was defined as acute for a single episode lasting less than 24 weeks,
recurrent if a patient experienced a second or subsequent episode of ENL occurring 28 days or
more after stopping treatment for ENL and chronic if occurring for 24 weeks or more during
which a patient has required ENL treatment either continuously or where any treatment free
period had been 27 days or less[6].
Data were collected on individuals, at a single attendance at a participating centre, who were
diagnosed with their first episode of ENL, a new episode of ENL in a patient previously diag-
nosed with ENL who was not receiving treatment for ENL or a deterioration of ENL while on
ENL specific treatment. Patients with ENL on treatment who had no new or deteriorating
symptoms, those diagnosed with a leprosy Type 1 reaction, those with Lucio’s phenomenon or
a drug reaction at enrolment were excluded. Recruitment of the first individual occurred on 9th
May 2012 and the last on 30th July2013. The period of recruitment at the non-UK centres ran-
ged from 181–425 days. Patients underwent the usual clinical examination and investigations
were performed only if that was the standard of care at the centre.
Using standardized definitions of symptoms and signs and a data collection form that had
been agreed by all of the participating groups; demographic, clinical and laboratory data were
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recorded including evidence of any nerve function impairment (NFI) using voluntary muscle
and Semmes-Weinstein monofilament sensory testing (which was the standard of care in all
but one centre). New NFI was defined as NFI present for less than six months. Temperature
measurements were taken from the axilla, oral cavity or tympanic membrane depending on the
preference of each individual centre. Fever was defined as a temperature of greater than 37.5°C.
The Wong-Baker Pain Rating Scale (range 0 “No pain” to 5 “Hurts worst”) [21] was used to
assess pain. A physician determined assessment of ENL severity (mild or moderate or severe)
was recorded. No attempt was made to standardise the severity assessments of the experienced
study physicians prior to data collection because it was deemed beyond the scope of the study.
The anonymised data were entered into an Excel database and analysed using Stata 13 (Sta-
taCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). The dif-
ferences between groups was assessed using odds ratios, the MannWhitney test, Chi squared
test or ANOVA. The level for statistical significance was set at p 0.05.
Ethics Statement
The study was routine. At all centres the data collected was that which pertained to the stan-
dard of care. At some centres no ethical approval was necessary. However Institutional Review
Board approval was obtained for the centres in Brazil, Nepal and the Philippines. A mixture of
written and verbal consent was obtained from the individuals studied.
Results
Data were collected on 292 patients. The demographics, Ridley-Jopling classification of the
patients’ leprosy, HIV status, type of ENL and physician determined severity of ENL are shown
in Table 1.
There were significant differences between centres in the study for the age of the patients
(p = 0.001), Brazilian patients had the highest median age of 37 years and Ethiopian patients
the lowest at 24 years. There were differences between centres with respect to Ridley-Jopling
classification (p<0.001) although the majority of patients at each centre had LL. The propor-
tion of patients with BL leprosy was considerably higher at the two Indian centres, at more
than 38%, compared to the other centres.
There was an even distribution of acute, recurrent and chronic ENL in the study group.
However a greater proportion of patients were deemed to have moderate or severe ENL than
mild disease by the study physicians. There were significant differences between centres with
respect to physician determined severity (p<0.001). A greater proportion of patients at the
two Indian centres were categorised as having moderate ENL than elsewhere. Individuals with
chronic ENL were more likely to be categorised as having severe disease than those with acute
ENL [OR:2.75; 95% CI:1.54–4.91] or recurrent ENL [OR:4.29; 95% CI: 2.39–7.91].
The median duration of ENL at the time of enrolment in 106 of the 143 individuals who
presented with ENL at the time of leprosy diagnosis was calculated and was 444 days [Range
0–6253]. The median duration of the episode of ENL studied in this study was seven days.
Pain was the commonest symptom reported by patients. 279 (96.5%) ENL patients report-
ing some degree of pain. The location and frequency of the pain is demonstrated in Fig 1. The
median number of symptoms reported by patients excluding pain was 4 [Range 0–12]. Fig 2
shows the distribution of the different symptoms. Patients with severe ENL were more likely to
have more symptoms of ENL than those with mild or moderate ENL. Sixty-eight (23.3%) indi-
viduals complained of depression.
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The median pain score using the Wong-Baker Pain Rating Scale was four (“hurts whole
lot”) which is the second highest score possible. Of the 289 patients for whom pain data were
collected, 169 (58.5%) reported pain intensity at one of the two highest possible levels (4 or 5).
The types of skin lesions and other organ involvement associated with ENL in the patients
is shown in Table 2 for the group as a whole and the individuals centres.
Fever was documented in 56 of 283 (19.8%) patients in contrast to the 217 (76.7%) who
reported fever. The highest fever documented was 40.5°C. There was no significant difference
in temperature between individuals with different types of ENL. However the group with
severe ENL were significantly more likely to have a documented fever than those with mild
ENL [OR:6.34; 95% CI: 2.13 to 18.84] or moderate ENL [OR:4. 95; 95% CI: 2.39 to 10.27].
There were no significant difference in the degree of fever exhibited by individuals in the differ-
ent severity classifications of ENL Fig 3.
The morphology of cutaneous lesions showed that 90.8% of individuals had papular or nod-
ular lesions. 14% had vesicles, bullae or pustular lesions. Erythema multiforme-like lesions
were documented in 4.4%. The frequency of the different types of skin lesion is illustrated in
Table 1. Demographic and clinical data of leprosy patients with ENL (n = 4 patients from UK not shown as a subgroup).
Centre ALL
(n = 292)
BRAZIL
(n = 47)
ETHIOPIA
(n = 51)
INDIA—
BLP
(n = 62)
INDIA—
TLM
(n = 60)
NEPAL
(n = 47)
PHILIPPINES
(n = 21)
Male: Female 2.8:1
(215:77)
3.7:1 1.1:1 3.8:1 5:1 3.3:1 20:1
Median Age (years, [Range]): 32 [12–
73]
37 [19–73] 24 [12–55] 32 [14–68] 30 [12–65] 30 [18–
60]
28 [21–50]
Leprosy type: n (%) Borderline
borderline (BB)
leprosy
5 (1.7) 0 (0) 3 (5.9) 1 (1.6) 1 (1.7) 0 (0) 0 (0)
BL leprosy 65 (22.3) 7 (14.9) 7 (13.7) 24 (38.7) 23 (38.3) 3 (6.4) 0 (0)
LL 222 (76.0) 40 (85.1) 41(80.4) 37 (59.7) 36 (60.0) 44 (93.6) 21 (100)
Median Mean Bacterial
Index (BI) at leprosy
diagnosis (288 BI available)
4 [0–6] 4.5 [1.25–
6]
3.5 [0–6] 4 [0.4–6] 4 [2–6] 4 [1–5.25] 5 [4.33–5]
Reaction status at leprosy
diagnosis: n (%)
None 113 (38.7) 32 (68.1) 22 (43.1) 12 (19.4) 12 (20.0) 20 (42.6) 13 (61.9)
Type 1 13 (4.5) 0 (0) 3 (5.9) 0 (0) 0 (0) 6 (12.8) 3 (14.2)
ENL 143 (49.0) 13 (27.7) 26 (51.0) 49 (79.0) 35 (58.3) 19 (40.4) 1 (4.8)
Neuritis 23 (7.9) 2(4.3) 0 (0) 1 (1.6) 13 (21.7) 2 (4.3) 4 (19.0)
MDT status: (n = 291) n (%) No previous
MDT
17 (5.8) 2 (4.3) 10 (19.6) 4 (6.5) 1 (1.7) 0 (0) 0 (0)
Current 101 (34.6) 11 (23.4) 8 (15.7) 12 (15.4) 37 (61.7) 31 (66.0) 2 (9.5)
Completed 173 (59.2) 34 (72.3) 33 (64.7) 45 (72.6) 22 (36.7) 16 (34.0) 19 (90.5)
HIV status: n (%) Negative 121 (41.4) 22 (46.8) 49 (96.1) — — 47 (100) ——
Positive 1 (0.003) — 1 (2.0) — — 0 (0) ——
Not known 170 (58.2) 25 (53.2) 1 (2.0) 62 (100) 60 (100) 0 (0) 21 (100)
ENL type: n (%) Acute 100 (34.2) 17 (36.2) 21 (41.2) 21 (33.9) 24 (40.0) 9 (19.1) 8 (38.1)
Recurrent 95 (32.5) 12 (25.5) 11 (21.6) 24 (38.7) 30 (50.0) 16 (34.0) 1 (4.8)
Chronic 97 (33.2) 18 (38.3) 19 (37.3) 17 (27.4) 6 (10.0) 22 (46.8) 12 (57.1)
Physician determined ENL
severity (n = 289): n (%)
Mild 53 (18.3) 10 (21.3) 3 (5.9) 21 (33.9) 2 (3.3) 16 (34.0) 1 (4.8)
Moderate 114 (39.4) 14 (29.8) 16 (31.4) 31 (50.0) 49 (81.7) 2 (4.3) 0 (0)
Severe 122 (42.2) 23 (48.9) 30 (58.8) 10 (16.1) 9 (15.0) 29 (61.7) 20 (95.2)
doi:10.1371/journal.pntd.0004065.t001
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Fig 1. Location of pain in ENL.
doi:10.1371/journal.pntd.0004065.g001
Fig 2. Symptoms other than pain in ENL.
doi:10.1371/journal.pntd.0004065.g002
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Fig 4. The size of the largest ENL lesion was not associated with physician determined severity
although the number of individuals with ulcerated or necrotic skin lesions increased as ENL
was judged to be more severe but these differences were not statistically significant. However
the number of skin lesions and the severity of ENL were correlated. Individuals with more than
20 skin lesions were more likely to have moderate or severe ENL than those classified as having
mild disease (p<0.001) (Fig 5).
The examination findings also revealed significant amounts of extra-cutaneous pathology.
Peripheral oedema was present in 153 (52.4%) of individuals, large joint arthritis in 70 (24%),
lymphadenitis in 43 (14.7%) and orchitis was present in 29 of the 215 (13.5%) men. Other
organ involvement is shown in Fig 6. Oedema was more often present at two or three sites
(hands, feet or face) in those with more severe ENL.
NFI was present in 150 (51.3%) individuals and of those 67 (22.9%) met the criteria for hav-
ing new NFI. The presence of NFI was significantly associated with the duration of ENL in the
106 individuals who presented with ENL at the time of leprosy diagnosis see Fig 7 (p = 0.035).
Patients were prescribed a wide variety of treatments for their ENL. Data were available for
277 individuals. ENL treatment using one drug occurred in 193 (69.7%), two drugs in 73
(26.4%) and three or more drugs in 11 (4%). Table 3 shows the ENL treatment prescribed at
the study visit. The three most common treatments prescribed were prednisolone, predniso-
lone and clofazimine and thalidomide.
Table 2. Clinical features of ENL (n = 4 patients from UK not shown as a subgroup).
Centre ALL
(n = 292)
BRAZIL
(n = 47)
ETHIOPIA
(n = 51)
INDIA—BLP
(n = 62)
INDIA—TLM
(n = 60)
NEPAL
(n = 47)
PHILIPPINES
(n = 21)
Skin lesions
Nodules 258 43 43 42 60 47 20
Subcutaneous
nodules
69 19 23 23 0 1 0
Papules 52 19 11 6 5 6 4
Plaques 28 12 7 4 0 5 0
Pustules 29 4 6 9 1 4 4
Vesicles 12 7 4 0 1 0 0
Bullae 10 2 3 0 1 3 0
Erythema multiforme-
like
13 12 1 0 0 0 0
Necrotic 11 0 0 7 1 3 0
Ulcerated 48 1 16 8 12 8 3
Other
Documented Fever 56 3 18 6 6 13 9
Oedema 153 20 35 41 36 13 5
NFI 150 29 21 30 36 18 14
Arthritis 105 11 22 31 19 14 6
Lymphadenitis 43 8 4 14 1 10 4
Dactylitis 40 5 11 11 5 7 0
Orchitis 29 7 2 5 1 8 6
Rhinitis 23 12 9 0 0 2 0
Ocular inﬂammation 15 0 1 4 5 3 1
doi:10.1371/journal.pntd.0004065.t002
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Fig 3. The degree of fever (temperature > 37.5°C) was not significantly different between groups with mild, moderate or severe ENL.
doi:10.1371/journal.pntd.0004065.g003
Fig 4. The frequency of the morphology of skin lesions in ENL (EM = erythemamultiforme).
doi:10.1371/journal.pntd.0004065.g004
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Fig 5. Number of skin lesions and severity of ENL.
doi:10.1371/journal.pntd.0004065.g005
Fig 6. Organ involvement in ENL.
doi:10.1371/journal.pntd.0004065.g006
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Discussion
This is the first systematic study of the clinical features of ENL and the profile of patients is
similar to previous retrospective studies[1, 2, 19, 22]. The majority of patients are young, male
and have lepromatous leprosy and a high mean BI. These data confirm that many individuals
have chronic and severe disease. In this study 34.2% of individuals had acute ENL and a pro-
portion of these will continue to experience ENL for longer than six months and therefore be
reclassified as recurrent or chronic. Chronic ENL is significantly more likely to be classified
severe than acute or recurrent ENL. This carries further weight when one considers that
chronic ENL is probably the predominant type in referral centres where ENL is most likely to
be managed[1, 6, 23].
Our study highlights the painful nature of ENL. Pain was reported by 96.5% of patients and
was the most common symptom. Although the painful nature of ENL is recognised by clini-
cians this unpleasant feature of the disease is not prominently reflected in the literature. Using
the semi-quantitative Wong-Baker Pain Rating Scale we were also able to show that not only is
pain frequent but it is also severe.
In the retrospective study from Nepal[19] 76% of patients had joint pain, 52% nerve pain,
30% bone pain and 10% muscle pain although it is not clear how these were defined nor
whether these symptoms were solely attributable to ENL. The most frequent site of pain due to
ENL in our study was the skin which is not surprising given that skin lesions are a defining fea-
ture of the condition. The next commonest site for pain was the joints with 36.3% of individu-
als affected. Bone, muscle, digit and nerve pain were almost equally prevalent affecting 29.4–
31.5% of individuals. The differences between these two studies are likely to be due to the meth-
odological differences employed. The large number of people affected by severe pain suggests
that patients experiencing ENL should have a formal pain assessment. Adequate analgesia in
Fig 7. Duration of ENL and presence of nerve function impairment (NFI).
doi:10.1371/journal.pntd.0004065.g007
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addition to immunomodulatory therapy is likely to be beneficial until control of the ENL has
been established. Given the different organs that exhibit pain during ENL different analgesic
regimes may be required. It was beyond the scope of this study to assess the type of pain experi-
enced by patients with ENL but patients with leprosy experience different types of pain which
require different interventions[24]
Fever is regarded as one of the hallmarks of ENL so we found it interesting that only 19.8%
of patients had a documented fever on examination whilst 74.3% complained of fever. Feuth
et al reported fever as a symptom in 78%. We conclude that a large proportion of patients expe-
rience fever or feel feverish due to the systemic inflammatory nature of ENL but that this does
not necessarily result in actual pyrexia or the pyrexia may have subsided by the time they pres-
ent. Although individuals classified as having severe ENL were more likely to be febrile than
those with milder forms of ENL the degree of fever was not significantly different. These find-
ings with respect to fever have implications for case definitions and severity assessments of
ENL.
Table 3. ENL treatment prescribed for patients at the study assessment.
ENL treatment ALL BRAZIL ETHIOPIA INDIA—
BLP
INDIA—
TLM
NEPAL PHILIPPINES Type of ENL
Number
(%)
n = 277
(n = 47) (n = 47) (n = 60) (n = 56) (n = 47) (n = 20) ACUTE RECURRENT CHRONIC
Monotherapy Prednisolone 141 (50.9) 2 (4.3) 28 (59.6) 23
(33.3)
40
(71.4)
28
(59.6)
20 (100) 61 41 39
Clofazimine 0 (0) 0 0 0
Thalidomide 41 (14.8) 37
(78.7)
3 (5.0) 1 (2.1) 16 14 11
Pentoxifylline 3 (1) 3 (5.0) 1 1 1
Non-steroidal anti-
inﬂammatory drug
(NSAID)
8(2.9) 1 (2.1) 7 (11.7) 4 1 3
Two drugs Prednisolone and
clofazimine
55(19.9) 18 (38.3) 17
(28.3)
14
(25.0)
6 (12.8) 12 27 16
Prednisolone and
thalidomide
8(2.9) 3 (6.4) 3 (5.0) 1 (1.8) 1 (2.1) 1 2 5
Prednisolone and
azathioprine
3 (1) 3 (6.4) 0 0 3
Prednisolone and
pentoxifylline
6(2.2) 4 (8.5) 2 (3.3) 2 0 4
Prednisolone and
NSAID
1(0.4) 1 (2.1) 0 1 0
Three drugs
or more
Prednisolone,
clofazimine and
thalidomide
5(1.8) 2 (3.3) 3 (6.4) 2 0 3
Prednisolone,
clofazimine and
azathioprine
4(1.4) 4 (8.5) 0 1 3
Prednisolone,
pentoxifylline and
thalidomide
1(0.4) 1 (2.1) 0 0 1
Prednisolone,
clofazimine,
thalidomide and
NSAID
1(0.4) 1 (1.8) 0 0 1
doi:10.1371/journal.pntd.0004065.t003
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The cutaneous manifestations of ENL are more diverse than those in the case definition
used in this study. The morphology of skin lesions other than papules and nodules is worthy of
note in terms of the wider differential diagnoses that incorporate such lesions.
The number of inflammatory skin lesions appears to be related to severity and our study
suggests the cut off is 20, a number that can be counted accurately.
The extracutaneous manifestations of ENL suggest that oedema is a common problem and
a possible marker of severity. The prevalence of oedema was less than that described by Feuth
et al but their methodology enabled them to capture data from multiple assessments of individ-
ual patients.
The high levels of NFI associated with ENL is significant (and in keeping with the data of
Feuth et al from Nepal) because “neuritis” due to ENL is not well understood and thalidomide
the gold standard treatment is not thought to be effective in the management of ENL associated
neuritis and NFI. Most authorities advocate that this entity is treated with prednisolone. It is
also important to recognise that we do not fully understand the potential neurotoxic adverse
effects of thalidomide in individuals with ENL[10, 25].
The prevalence of cutaneous nodules, oedema and NFI as the three most common clinical
signs in the cohort as a whole is reflected at the level of the individual centres. The two com-
monest clinical signs at each centre were either nodules and oedema or nodules and NFI. It
would appear that ENL manifests in broadly the same way at the different centres, although
this inference should be treated with caution due to the variety of potential confounding factors
such as: ENL treatment, duration of ENL and MDT status.
The treatment of ENL at our centres varies considerably. Most patients were treated with
prednisolone either alone or in combination with at least one other agent. Thalidomide is not
available in Ethiopia or the Philippines. Its use is severely restricted in Nepal. In contrast
patients are referred to the other centres for management of ENL with thalidomide. Although
thalidomide is very effective in the management of ENL, 26.8% (15/56) patients in this study
treated with the drug required at least one additional agent. One other striking feature about
the treatment prescribed to these patients was that none of them received clofazimine mono-
therapy. Clofazimine was used in combination with prednisolone and its effectiveness as a ste-
roid sparing agent should be properly assessed.
The limitations of this study were that, although data were collected systematically, we were
only able to gather clinical data at one point in time. The study took place in referral centres in
different countries and populations. We made no attempt to standardise the different physi-
cians assessment of patients or ENL severity and we did not control for treatment that had
been prescribed prior to the study assessment. The Wong-Baker Pain Rating Scale was devel-
oped in the USA for the assessment of children with pain and has not been validated in adults
with ENL. It did not pose any problems of application in the different settings in which we
used it. However these factors may account for some of the observed differences between cen-
tres. It is possible that there are genuine differences in ENL or the health-seeking behaviour of
patients in these diverse settings and further work needs to consider these possibilities.
We have shown that ENL managed at leprosy referral centres is severe, very painful, associ-
ated with a high prevalence of neurological impairment and poses a considerable management
problem even where thalidomide is available. This study provides the first detailed data of the
prevalence of the clinical features of ENL and their relationship to physician determined sever-
ity that should be used to inform measures of ENL severity and outcome measures for much
needed treatment studies.
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